Dystrogen Therapeutics Announces First in Man Dosing of Novel Chimeric Cell Therapy for Duchenne Muscular Dystrophy and Reports 6-week Clinical Outcomes

Dystrogen Therapeutics, Corp. the leader in chimeric cell therapies, today announced positive results from an ongoing study conducted in Poland under a hospital exemption protocol of DT-DEC01 (Dystrophin expressing chimeric (DEC) cells), the Company’s investigational engineered cell therapy for Duchenne muscular dystrophy (DMD).